May 11, 2020
Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
Dyno Therapeutics has entered collaboration with Novartis, to develop improved Adeno-Associated Virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases.